Shattuck Labs to Present at the Virtual Healthcare Conference
AUSTIN, TX and DURHAM, NC — Shattuck Labs, Inc. (NASDAQ: STTK), a leader in biotechnology, is excited to announce its participation in the 24th Annual Needham Virtual Healthcare Conference. The event is set to take place from April 7 to April 10, and Shattuck Labs will host presentations and one-on-one meetings during this important industry gathering.
Event Details and Presentation Schedule
During the conference, Shattuck's Chief Executive Officer, Dr. Taylor Schreiber, will deliver a presentation on April 9 at 3:00 PM EDT. This will provide an excellent opportunity for attendees to gain insights into the company's innovative work in developing novel therapeutics targeting tumor necrosis factor (TNF) superfamily receptors.
Accessing the Conference
For those unable to attend live, a live webcast will be available on Shattuck’s official website in the Events and Presentations section. A replay of the presentation will also be archived for one month following the event, making it convenient for interested parties to catch up on the latest developments.
Insights into Shattuck's Lead Program: SL-325
One of the key focuses of Shattuck Labs is SL-325, a promising candidate that acts as a blocking antibody for Death Receptor 3 (DR3). This innovative therapy aims for a complete blockade of the DR3/TL1A pathway, which has been clinically validated. Preclinical studies suggest that SL-325 exhibits high affinity binding and offers enhanced activity compared to existing TL1A antibodies.
Advancement and Development Timeline
Recently, SL-325 completed a Good Laboratory Practice (GLP) toxicology study in non-human primates. Shattuck Labs anticipates filing an Investigational New Drug (IND) application in the third quarter of 2025, marking a significant step forward in its development timeline.
About Shattuck Labs, Inc.
Founded with a mission to address inflammatory and immune-mediated diseases, Shattuck Labs, Inc. (NASDAQ: STTK) is at the forefront of biotechnology, specializing in groundbreaking treatments. The company’s expertise in protein engineering fuels its development of SL-325, aiming to provide more effective solutions for patients suffering from inflammatory bowel disease (IBD) and related conditions.
Company Presence and Future Directions
Shattuck Labs operates from both Austin, Texas, and Durham, North Carolina, while continuously exploring future opportunities to expand its innovative pipeline. As the company focuses on driving the clinical translation of its research, it remains committed to enhancing patient care and treatment options.
Frequently Asked Questions
What does Shattuck Labs do?
Shattuck Labs focuses on developing novel therapeutics targeting immune-related diseases, particularly through its lead program SL-325.
When will SL-325 be available for clinical use?
The IND filing for SL-325 is expected in the third quarter of 2025, moving it closer to clinical trials.
Who will present at the Needham Virtual Healthcare Conference?
Dr. Taylor Schreiber, the Chief Executive Officer of Shattuck Labs, will be presenting.
Where can I watch the conference live?
A live webcast will be available on Shattuck’s official website during the conference.
What is the significance of the DR3/TL1A pathway?
The DR3/TL1A pathway plays a pivotal role in inflammatory responses, making it a critical target for therapeutic exploration.